ACADIA PHARMACEUTICALS INC. Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount
ACADIA PHARMACEUTICALS INC. (ACAD) had Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount of $9.20 million as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Compensation Related Costs
us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount · last filed 2026-02-26
- 2024-09-30: Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount $9.20M.
- 2024-06-30: Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount $9.60M.
- 2024-03-31: Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount $9.90M.
- 2023-12-31: Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount $10.10M.
| Period end | Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount |
|---|---|
| 2024-09-30 | $9.20M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $9.60M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $9.90M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $10.10M 10-K · filed 2024-02-28 |
| 2023-09-30 | $10.30M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $10.40M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $11.60M 10-Q · filed 2023-05-08 |
| 2022-09-30 | $12.10M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $13.30M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $13.90M 10-Q · filed 2022-05-05 |
| 2021-11-30 | $15.10M 10-Q · filed 2024-11-07 |
| 2021-11-02 | $15.10M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |